Tag Archives: Pharma

Exclusive | KKR Pushes Further Into Healthcare With Deal for Pharma Royalty Business – The Wall Street Journal

Exclusive | KKR Pushes Further Into Healthcare With Deal for Pharma Royalty Business  The Wall Street Journal KKR Pushes Further Into Healthcare With Deal for Pharma Royalty Business  Yahoo Finance KKR & Co. Acquires Majority Ownership Stake In HCRx  Nasdaq KKR buys HealthCare Royalty Partners as firm deepens bet on life sciences  Endpoints News KKR Announces Strategic Acquisition of HealthCare Royalty Partners, Expanding the …

Read More »

Merck joins Big Pharma cost-cutting crowd, revealing plan to save $3B annually by 2027 – Fierce Pharma

Merck joins Big Pharma cost-cutting crowd, revealing plan to save $3B annually by 2027  Fierce Pharma Merck plans $3 billion cost cuts by end of 2027, narrows full-year outlook  CNBC Merck Stock Falls After Layoff Announcement, Gardasil Sales Drop  Investor’s Business Daily Merck to Lay Off Workers and Narrows Guidance as Earnings Fall – WSJ  The Wall Street Journal Our Q2 2025 financial results  Merck.com …

Read More »

AstraZeneca to invest $50 billion in the U.S. as pharma tariffs weigh

AstraZeneca to invest  billion in the U.S. as pharma tariffs weigh

The office building of international biopharmaceutical company AstraZeneca. Cfoto | Future Publishing | Getty Images AstraZeneca on Monday said it plans to invest $50 billion in bolstering its U.S. manufacturing and research capabilities by 2030, becoming the latest pharmaceutical firm to ramp up its stateside spending in the wake of U.S. trade tariffs. The Anglo-Swedish biotech company, which is headquartered …

Read More »

Bristol Myers braves failed Reblozyl phase 3, plans FDA talks for potential anemia expansion – Fierce Pharma

Bristol Myers braves failed Reblozyl phase 3, plans FDA talks for potential anemia expansion  Fierce Pharma BMS’ Anemia Drug Reblozyl Flunks Phase III Myelofibrosis Trial  BioSpace Bristol Myers Squibb’s Reblozyl fails Phase 3 in anemia; Sanofi, Blueprint deal closes  Endpoints News Retail Chatter On BMY Doubles In 24 Hours With Drug Failing To Meet Primary Goal: Here’s What Investors Are Thinking  Stocktwits Luspatercept Plus …

Read More »